awmsg logo



turoctocog alfa (NovoEight®)


Reference No. 1634

Publication date:
08/05/2014


Appraisal information

turoctocog alfa (NovoEight®) 250 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 500 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 1000 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 1500 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 2000 units powder and solvent for solution for injection
turoctocog alfa (NovoEight®) 3000 units powder and solvent for solution for injection


Company: Novo Nordisk Ltd
BNF category: Cardiovascular system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 07/05/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, turoctocog alfa (NovoEight®) cannot be endorsed for use within NHS Wales for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).
Statement of Advice (SOA)
Download